Rosen Law Firm initiates securities fraud class action against Capricor Therapeutics, giving investors until Sept 28, 2026 to seek lead plaintiff role
Executive summary: Rosen Law Firm filed a class action lawsuit alleging Capricor Therapeutics made material misstatements about its clinical data and Biologics License Application, affecting shareholders who bought shares between December 17, 2025 and July 26, 2026. The lawsuit seeks recovery for investors allegedly harmed by inflated stock prices based on misleading disclosures, with a lead plaintiff deadline of September 28, 2026.
Who is involved: Capricor Therapeutics (NASDAQ: CAPR), Rosen Law Firm, and shareholders who purchased CAPR securities during the class period.
Likely next: Investors may file motions for lead plaintiff appointment by September 28, 2026; court will evaluate adequacy of representation and claims.
On August 13, 2026, Rosen Law Firm announced a class action lawsuit on behalf of purchasers of Capricor Therapeutics (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026. The lawsuit alleges violations of federal securities laws related to disclosures concerning the company's Biologics License Application and clinical trial data. Investors in the defined class period have until September 28, 2026 to move for appointment as lead plaintiff. This follows a series of similar alerts from other law firms regarding the same underlying allegations.
Timeline
- — CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit (PR Newswire)
- — CAPR Deadline Alert: SueWallSt Reminds Capricor Therapeutics, Inc. (CAPR) Investors of Securities Class Action Deadline on September 28, 2026 (PR Newswire)
- — INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR (PR Newswire)
- — CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law (PR Newswire)
- — Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR (PR Newswire)
- — INVESTOR ALERT: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit (PR Newswire)
Analysis — what this means
Likely next events
- September 28, 2026: Deadline for investors to move for lead plaintiff appointment in the Capricor securities class action.
Sectors affected
- Biotechnology
- Pharmaceuticals
Regulatory implications
- Potential SEC scrutiny over disclosure practices in clinical trial reporting for biotech firms seeking FDA approval.
Historical parallels
- Securities class action against Biogen (2021) over Alzheimer’s drug Aduhelm disclosures.
- Securities lawsuit against Theranos (2018) related to false blood test claims.
Key entities
Sources
- CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit — PR Newswire
- CAPR Deadline Alert: SueWallSt Reminds Capricor Therapeutics, Inc. (CAPR) Investors of Securities Class Action Deadline on September 28, 2026 — PR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR — PR Newswire
- CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law — PR Newswire
- Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR — PR Newswire
- INVESTOR ALERT: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit — PR Newswire
Related cases
- Capricor Therapeutics faces a looming lead plaintiff deadline that could shape the outcome of its securities class action lawsuit
- Rosen Law Firm alerts Capricor Therapeutics investors of September 2 lead plaintiff deadline in securities fraud class action
- Capricor Therapeutics faces a class‑action securities lawsuit alleging violations of exchange‑act provisions, triggering potential legal costs and investor scrutiny
- SBS Law invites investors to lead a securities‑fraud class action against Capricor Therapeutics, highlighting a broader pattern of similar shareholder‑rights actions
- ClaimsFiler alerts Capricor Therapeutics investors with over $100k losses to file lead plaintiff applications by September 28, 2026
- Capricor Therapeutics faces a class-action securities lawsuit alleging violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934